Skip to main content
Premium Trial:

Request an Annual Quote

Life Technologies to Market Gen-Probe's Aneuploidy Kits

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Life Technologies will commercialize Gen-Probe's Elucigene QST*R aneuploidy test kits under the Applied Biosystems name in certain markets around the world, the firm announced over the weekend.

Life Technologies will sell the test kits in Eastern Europe, Asia, Africa, Australia, Latin America, and Canada, under the agreement. However, the kits will not be available for sale in the US.

According to Andy Felton, director of the Genetic Systems Division of Life Technologies, the kits will enable rapid analysis "of the most common viable human aneuploidies or chromosomal abnormalities, including Down syndrome."

The kits are labeled for use with Applied Biosystems' capillary electrophoresis systems, including the firm's new 3500 Series Genetic Analyzer. Life Technologies expects to begin selling the kits in mid-2010.

"This partnership will enable a wider global presence for our technology which we deeply believe helps improve prenatal care," Mike Webb, general manager of Elucigene products for Gen-Probe Life Sciences, said in a statement.

Financial and other terms of the alliance were not disclosed.

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.